跳至主要内容
临床试验/ISRCTN15982148
ISRCTN15982148进行中(未招募)3 期

The effect of ulinastatin on sepsis-related organ failure in children: a multicenter randomized controlled trial

Guangdong Techpool Bio-pharma Co., Ltd.0 个研究点目标入组 364 人开始时间: 2024年8月29日最近更新:
适应症

试验速览

阶段
3 期
状态
进行中(未招募)
发起方
入组人数
364

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. 28 days < age = 18 years
  • 2. There is clear evidence of infection
  • 3. Meet diagnostic criteria for sepsis: infection + pSOFA and/or Phoenix Sepsis Score (PSS) =2

排除标准

  • 1. Received immunomodulatory therapy within 2 months before enrollment, such as Xuebijing and thymosin
  • 2. Use of high-dose non-steroidal anti-inflammatory drugs within two days before enrollment; The daily dose of glucocorticoids > 5 mg/kg or greater than 500 mg/day within two days before enrollment
  • 3. Palliative treatment without enough life support treatment
  • 4. Receive ulinastatin treatment prior to enrollment
  • 5. Previous history of allergy to ulinastatin or any of its components
  • 6. Children with terminal disease

研究者

发起方
Guangdong Techpool Bio-pharma Co., Ltd.

相似试验